How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Tata has gone for an all-new cabin layout for the 2025 Sierra that not only looks upmarket but also packs in plenty of tech The 2025 Tata Sierra is finally here! New design, a new-turbo-petrol from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback